ArticleBlood science (Baltimore, Md.)2024

Subcutaneous daratumumab in Chinese patients with relapsed or refractory multiple myeloma: an open-label, multicenter, phase 1 study (MMY1010).

Gang An et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.